Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, announced its participation in two investor conferences. The first is a panel discussion at the Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:20 p.m. ET, focusing on immuno-oncology. The second is a corporate presentation at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 12 p.m. ET. A live audio webcast of the Canaccord presentation will be available on the Harpoon website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences:
- A panel discussion, “For Your IOnly – Progress, Challenges in Immuno-Oncology” at the Wedbush PacGrow Healthcare Conference (hybrid) at 2:20 p.m. ET (11:20 a.m. PT) on Tuesday, August 9, 2022; and
- A corporate presentation at the Canaccord Genuity 42nd Annual Growth Conference in Boston, at 12 p.m. ET (9 a.m. PT) on Wednesday, August 10, 2022.
A live audio webcast of the Canaccord presentation will be available in the Investors section of the Harpoon Therapeutics website at www.harpoontx.com with an archived replay available following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “look forward,” “plan,” “target,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the development and advancement of Harpoon Therapeutics’ platforms and product candidates, including progress, timing, planned milestones, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics’ cash resources. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in Harpoon Therapeutics’ annual report on Form 10-K for the month ended March 31, 2022 and other filings by Harpoon Therapeutics. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contacts:
Investors:
Robert Uhl
ICR Westwicke
858-356-5932
robert.uhl@westwicke.com
Media:
uncapped communications
862-368-4464
media@harpoontx.com
Company:
Georgia Erbez
Chief Financial Officer
650-443-7400
FAQ
When will Harpoon Therapeutics participate in investor conferences?
What is the topic of Harpoon's panel discussion on August 9, 2022?
Where can I watch the webcast of Harpoon Therapeutics' presentation?
What are the timings for Harpoon's presentations at the investor conferences?
